TEVA

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.03
Percentage change 0.18	%

Peers: VTRS PRGO AMRX GSK BMY PFE MRK NVS ABBV JNJ

| Held by: IEFA EFA EFV IXUS EIS SPDW IDEV FNDF EFG IVLU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	0.01%	Shs Outstand	1.15B	Perf Week	-2.49%
Market Cap	18.84B	Forward P/E	5.96	EPS next Y	2.76	Insider Trans	-90.45%	Shs Float	1.15B	Perf Month	-5.14%
Enterprise Value	34.09B	PEG	-	EPS next Q	0.63	Inst Own	63.06%	Short Float	3.48%	Perf Quarter	28.16%
Income	-1286.00M	P/S	1.14	EPS this Y	1.95%	Inst Trans	5.90%	Short Ratio	3.48	Perf Half Y	-23.55%
Sales	16.56B	P/B	3.01	EPS next Y	8.62%	ROA	-3.17%	Short Interest	39.87M	Perf YTD	-25.46%
Book/sh	5.46	P/C	11.10	EPS next 5Y	7.74%	ROE	-18.98%	52W High	22.80 -27.94%	Perf Year	-3.24%
Cash/sh	1.48	P/FCF	9.05	EPS past 3/5Y	- -9.62%	ROIC	-5.65%	52W Low	12.47 31.81%	Perf 3Y	116.18%
Dividend Est.	-	EV/EBITDA	7.73	Sales past 3/5Y	1.38% -0.43%	Gross Margin	49.01%	Volatility	1.95% 2.52%	Perf 5Y	46.56%
Dividend TTM	-	EV/Sales	2.06	EPS Y/Y TTM	-175.90%	Oper. Margin	20.40%	ATR (14)	0.47	Perf 10Y	-73.35%
Dividend Ex-Date	Nov 27, 2017	Quick Ratio	0.74	Sales Y/Y TTM	3.38%	Profit Margin	-7.76%	RSI (14)	43.24	Recom	1.40
Dividend Gr. 3/5Y	- -	Current Ratio	1.03	EPS Q/Q	249.11%	SMA20	-2.43%	Beta	0.63	Target Price	24.29
Payout	-	Debt/Eq	2.71	Sales Q/Q	0.84%	SMA50	-3.58%	Rel Volume	0.86	Prev Close	16.40
Employees	36167	LT Debt/Eq	2.64	Earnings	Jul 30 BMO	SMA200	-5.45%	Avg Volume	11.47M	Price	16.43
IPO	Feb 16, 1982	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.43% -2.44%	Trades		Volume	4,234,321	Change	0.18%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-06-25	Initiated	Goldman	Buy	$24
May-28-25	Initiated	Truist	Buy	$25
May-12-25	Upgrade	JP Morgan	Neutral → Overweight	$23
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy	$10
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy	$10 → $13
Jun-14-22	Resumed	UBS	Neutral	$10
May-17-22	Upgrade	BofA Securities	Underperform → Neutral	$9

Show Previous Ratings

Jul-11-25 08:31AM	TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-09-25 12:55AM	Teva Partners with Fosun Pharma to Advance Novel Cancer Immunotherapy TEV-56278 (Insider Monkey)
Jul-08-25 05:32AM	Teva's Ajovy Shows Sustained Long-Term Efficacy in Migraine Prevention Trial (Insider Monkey)
Jun-26-25 04:30PM	Teva Releases Q2 2025 Aide Memoire (GlobeNewswire)
11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
06:22PM	Loading…
Jun-25-25 06:22PM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
04:30PM	Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 (GlobeNewswire)
08:44AM	Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys? (Motley Fool)
Jun-24-25 11:33AM	Teva reports final analysis of migraine prevention trial of Ajovy (Clinical Trials Arena)
04:25AM	Goldman Sachs Starts Teva Pharma (TEVA) at Buy on Branded Drug Growth (Insider Monkey)
Jun-23-25 09:22AM	J&J Adds More Than $15B in Six Months: How to Play JNJ Stock? (Zacks)
03:00AM	Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY (fremanezumab) for the Prevention of Chronic and Episodic Migraine (GlobeNewswire)
Jun-17-25 12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks)
10:00AM	Generic Drugmakers Resist Trumps Calls for More U.S. Manufacturing (The Wall Street Journal)
09:10AM	Teva, Fosun Pharma partner to develop TEV-56278 (TipRanks)
07:23AM	Loading…
07:23AM	Teva to collaborate with Fosun Pharma for TEV-56278 (Pharmaceutical Technology)
Jun-16-25 08:30AM	Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology (GlobeNewswire)
03:06AM	Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters (Motley Fool)
Jun-13-25 02:08PM	The Israel-Iran conflict is casting a long shadow on the stock market. Here are the winners and losers. (MarketWatch)
Jun-10-25 05:00AM	Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris (Zacks)
Jun-09-25 09:29AM	3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats (Zacks)
Jun-07-25 09:40AM	CrowdStrike and McDonalds downgraded: Wall Streets top analyst calls (TipRanks)
Jun-06-25 01:40PM	Goldman Sachs initiates coverage on generic drugmakers, sees upside in Teva and Am (Investing.com)
Jun-03-25 05:30PM	Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer (GlobeNewswire)
07:16AM	Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement (GlobeNewswire)
May-31-25 02:14PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
May-30-25 09:05PM	New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025 (GlobeNewswire)
09:00PM	Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date (GlobeNewswire)
08:10AM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
May-29-25 04:25PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
01:50PM	Loading…
01:50PM	Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target (Insider Monkey)
08:00AM	Teva Reaffirms "Pivot to Growth" Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day (GlobeNewswire)
May-28-25 11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
03:06AM	Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead (Motley Fool)
May-27-25 08:25PM	Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408 (Insider Monkey)
05:30PM	Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA (GlobeNewswire)
04:30PM	Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June (GlobeNewswire)
03:44PM	Why Is Teva Stock Trading Higher On Tuesday? (Benzinga)
11:19AM	TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock? (Zacks)
08:30AM	Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma (GlobeNewswire)
May-26-25 09:47AM	Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA) (Insider Monkey)
May-22-25 01:56PM	Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes (GlobeNewswire)
09:07AM	JNJ Down 6% in 3 Months: How to Play the Stock Amid Various Challenges (Zacks)
May-20-25 05:22PM	Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt (GlobeNewswire)
04:30PM	Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy (GlobeNewswire)
May-19-25 04:52AM	Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes (GlobeNewswire)
04:52AM	Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031 (GlobeNewswire)
May-15-25 06:12PM	Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy (GlobeNewswire)
11:30AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
May-14-25 07:41AM	Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds Are Buying (Insider Monkey)
May-12-25 05:02PM	Why Teva Pharmaceuticals Stock Blasted 6% Higher Today (Motley Fool) +6.08%
04:14PM	Teva's Bold $700M Gamble: Will It Be Enough to Rescue Its Plummeting Stock? (GuruFocus.com)
07:00AM	Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy (GlobeNewswire)
May-09-25 05:09PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -6.31%
04:21AM	Teva Pharmaceutical Industries Limited (TEVA): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 11:12AM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
07:48AM	TEVA Beats on Q1 Earnings, Expects $700M Cost Savings by 2027, Stock Up (Zacks)
03:06AM	Teva Pharmaceutical Industries Ltd (TEVA) Q1 2025 Earnings Call Highlights: Strong Growth in ... (GuruFocus.com)
01:48AM	Why Teva Pharmaceutical Industries Limited (TEVA) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 04:16PM	Teva Stock Jumps On Outlook. CEO Touts 'Real Clarity' On Future Profits. (Investor's Business Daily) +9.18%
02:08PM	Why Teva Pharmaceutical Stock Is Soaring Today (Motley Fool)
01:01PM	Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says (Barrons.com)
10:49AM	Teva targets $2.5B sales for Austedo in 2027 while advancing innovative portfolio (Seeking Alpha)
10:47AM	Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Teva Pharmaceutical Industries (TEVA) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
08:47AM	Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter Report (Investor's Business Daily)
08:47AM	Teva Jumps As Profit Beats, Guidance Hike Outweighs Light Sales (Investor's Business Daily)
08:00AM	Teva rises as forex impact drives Q1 revenue miss (Seeking Alpha)
07:30AM	Teva Pharmaceutical's branded drugs boost first quarter profit (Reuters)
07:00AM	Teva to Host Innovation & Strategy Day on Thursday, May 29 in New York City (GlobeNewswire)
07:00AM	Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook Improved (GlobeNewswire)
May-06-25 02:50PM	Q1 2025 Corcept Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
05:49AM	FDA approves Selarsdi injection as interchangeable with Stelara (Pharmaceutical Technology)
May-05-25 09:50AM	Teva Pharmaceutical Industries Ltd. (TEVA) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 Earnings (Zacks)
07:49AM	Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with Stelara (ustekinumab) (GlobeNewswire)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
Apr-28-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-27-25 11:40PM	Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results (Seeking Alpha)
Apr-24-25 08:29PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
07:46AM	Johnson & Johnson Just Proved The Bears Wrong Again (Seeking Alpha)
Apr-21-25 08:21AM	Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? (Zacks)
03:51AM	Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now (Motley Fool)
Apr-17-25 08:03AM	Here's How You Should Play JNJ Stock After Q1 Earnings Beat (Zacks)
Apr-16-25 04:38AM	Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals (Zacks)
Apr-15-25 11:14AM	JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal (Zacks)
07:15AM	3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes (Zacks)
Apr-13-25 03:06AM	5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility (Motley Fool)
Apr-11-25 03:03PM	Teva Pharmaceutical Industries (TEVA): Among the Top Healthcare Stocks to Buy According to Billionaire David Einhorn (Insider Monkey)
Apr-10-25 07:46PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research) -9.46%
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha)
Apr-08-25 09:35AM	Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory (Insider Monkey)
Apr-07-25 08:00AM	Teva and Samsung Bioepis Announce Biosimilar EPYSQLI (eculizumab-aagh) Injection Now Available in the United States (GlobeNewswire)
07:30AM	Teva Announces FDA Filing Acceptance for AJOVY (fremanezumab) in Pediatric Episodic Migraine Prevention (GlobeNewswire)
Apr-04-25 11:10PM	Arcutis Biotherapeutics: Zoryve's Growth Impresses, But Valuation Is A Concern (Rating Upgrade) (Seeking Alpha) -7.07%
Apr-03-25 04:35PM	Top Stock Reports for Cisco, Caterpillar & CME (Zacks)
02:19PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
Apr-02-25 01:06PM	TCW Relative Value Mid Cap Fund Q4 2024 Commentary (Seeking Alpha)
Apr-01-25 01:05PM	Teva announces presentation of survey study on TEV-749 (TipRanks)

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Jun 12 '25	Sale	17.08	55,775	952,464	403,288	Jun 16 04:03 PM
Kalif Eliyahu Sharon	Officer	Jun 12 '25	Proposed Sale	17.08	55,775	952,466		Jun 12 04:18 PM
Shields Matthew	EVP, Global Operations	Jun 03 '25	Sale	17.02	6,206	105,628	9,989	Jun 05 05:08 PM
Shields Matthew	Officer	Jun 03 '25	Proposed Sale	17.02	6,206	105,628		Jun 03 03:59 PM
Sabag Mark	See "Remarks"	May 08 '25	Sale	18.04	337,915	6,097,304	150,996	May 12 04:00 PM
Sabag Mark	Officer	May 08 '25	Proposed Sale	18.04	337,915	6,097,324		May 08 02:34 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	70,961	1,128,642	48,384	Mar 07 04:05 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.73	15,174	238,757	8,077	Mar 06 04:11 PM
Hughes Eric A	See "Remarks"	Mar 05 '25	Sale	15.91	8,077	128,531	0	Mar 06 04:11 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.73	91,608	1,441,415	7,108	Mar 06 04:06 PM
Daniell Richard	Exec. VP, European Commercial	Mar 05 '25	Sale	15.91	48,764	775,991	0	Mar 06 04:06 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.73	15,514	244,107	280,042	Mar 06 04:03 PM
Francis Richard D	President and CEO	Mar 05 '25	Sale	15.91	8,259	131,427	271,783	Mar 06 04:03 PM
Daniell Richard	Officer	Mar 05 '25	Proposed Sale	15.83	70,961	1,123,585		Mar 05 04:29 PM
Daniell Richard	Exec. VP, European Commercial	Mar 03 '25	Sale	16.19	49,314	798,172	12,936	Mar 05 04:12 PM
Daniell Richard	Exec. VP, European Commercial	Mar 04 '25	Sale	15.56	12,936	201,253	0	Mar 05 04:12 PM
Hughes Eric A	See "Remarks"	Mar 03 '25	Sale	16.19	19,726	319,275	5,174	Mar 05 04:08 PM
Hughes Eric A	See "Remarks"	Mar 04 '25	Sale	15.56	5,174	80,495	0	Mar 05 04:08 PM
Francis Richard D	President and CEO	Mar 03 '25	Sale	16.19	24,892	402,889	251,783	Mar 05 04:04 PM
Francis Richard D	President and CEO	Mar 04 '25	Sale	15.56	6,450	100,347	245,333	Mar 05 04:04 PM
Fox Christine	Officer	Mar 04 '25	Proposed Sale	16.00	6,181	98,896		Mar 04 07:02 PM
McAvoy David R.	Officer	Mar 04 '25	Proposed Sale	16.00	4,827	77,232		Mar 04 06:57 PM
Hughes Eric A	Officer	Mar 04 '25	Proposed Sale	16.00	23,251	372,016		Mar 04 06:44 PM
Daniell Richard	Officer	Mar 04 '25	Proposed Sale	16.00	86,400	1,382,400		Mar 04 06:37 PM
Francis Richard D	Officer	Mar 04 '25	Proposed Sale	16.00	23,773	380,368		Mar 04 06:30 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 28 '25	Sale	16.21	55,750	903,462	147,941	Mar 04 04:02 PM
Francis Richard D	Officer	Mar 03 '25	Proposed Sale	16.46	31,342	515,889		Mar 03 01:14 PM
Hughes Eric A	Officer	Mar 03 '25	Proposed Sale	16.46	24,900	409,854		Mar 03 01:07 PM
Daniell Richard	Officer	Mar 03 '25	Proposed Sale	16.46	62,250	1,024,635		Mar 03 12:59 PM
Kalif Eliyahu Sharon	Officer	Feb 28 '25	Proposed Sale	16.21	55,750	903,463		Feb 28 11:52 AM
Francis Richard D	President and CEO	Feb 18 '25	Sale	16.95	75,506	1,279,661	209,444	Feb 19 04:03 PM
Francis Richard D	Officer	Feb 18 '25	Proposed Sale	16.95	75,506	1,279,661		Feb 18 12:38 PM
Sabag Mark	See "Remarks"	Feb 12 '25	Sale	16.25	177,626	2,886,565	204,964	Feb 14 04:03 PM
Sabag Mark	Officer	Feb 12 '25	Proposed Sale	16.25	177,626	2,886,555		Feb 13 08:06 AM
MIGNONE ROBERTO	Director	Dec 20 '24	Sale	22.01	286,000	6,294,031	695,000	Dec 26 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 20 '24	Proposed Sale	21.31	286,000	6,094,660		Dec 20 07:03 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '24	Sale	16.87	19,388	327,085	44,104	Nov 21 04:04 PM
Fox Christine	Officer	Nov 20 '24	Proposed Sale	16.87	19,388	327,085		Nov 20 11:39 AM
Daniell Richard	Exec. VP, European Commercial	Aug 12 '24	Sale	17.30	98,943	1,711,447	0	Aug 13 04:09 PM
Grant Angus	EVP, Business Development	Aug 09 '24	Sale	17.28	4,065	70,243	8,848	Aug 13 04:06 PM
Hughes Eric A	See "Remarks"	Aug 09 '24	Sale	17.38	45,060	782,972	0	Aug 13 04:02 PM
Daniell Richard	Officer	Aug 12 '24	Proposed Sale	17.30	98,943	1,711,444		Aug 12 04:09 PM
Hughes Eric A	Officer	Aug 09 '24	Proposed Sale	17.38	45,060	782,974		Aug 12 03:59 PM
Grant Angus	Officer	Aug 09 '24	Proposed Sale	17.28	4,065	70,243		Aug 09 03:59 PM
Hughes Eric A	See "Remarks"	Aug 01 '24	Sale	17.25	24,537	423,280	45,060	Aug 05 07:35 AM
Hughes Eric A	Officer	Aug 01 '24	Proposed Sale	17.25	24,537	423,281		Aug 01 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd. ADR

Upgrade your FINVIZ experience